FOR IMMEDIATE RELEASE - Baxter

BAXTER ANNOUNCES DIVESTITURE OF U.S. GENERIC
INJECTABLES BUSINESS TO HIKMA PHARMACEUTICALS – Page 2
“The divestiture of this business is driven by Baxter’s continued focus on
differentiated product offerings derived from the company’s formulation technologies
and enhanced packaging expertise,” said Camille Farhat, general manager of Baxter’s
Pharmaceuticals and Technologies business.
Baxter’s U.S. “multi-source” generic injectables business will be integrated into
West-Ward Pharmaceuticals Corp., the U.S. agent for, and wholly-owned subsidiary of,
Hikma Pharmaceuticals PLC. Customers can expect continued product supply and
service during the West-Ward transition.
West-Ward has a growing portfolio of generic products in the U.S., including
dozens of products commercially available and under development. Hikma
Pharmaceuticals is a fast-growing multinational group focused on developing,
manufacturing and marketing a broad range of both branded and non-branded generic
and in-licensed products. Subject to regulatory approvals and other conditions, the
companies expect to complete the transaction within the next three months.
Baxter purchased the Cherry Hill manufacturing facility in 2002, when it acquired
the business from ESI Lederle, a division of Wyeth. Sales of this business totaled
approximately $170 million in 2009. The company does not expect this transaction to
impact its previously-issued earnings guidance.
About Baxter
Baxter International Inc., through its subsidiaries, develops, manufactures and
markets products that save and sustain the lives of people with hemophilia, immune
disorders, infectious diseases, kidney disease, trauma, and other chronic and acute
medical conditions. As a global, diversified healthcare company, Baxter applies a
unique combination of expertise in medical devices, pharmaceuticals and biotechnology
to create products that advance patient care worldwide.
- more -